|
WuXi Biologics: Expanded the Suzhou stock solution production base, and obtained the exclusive CDMO cooperation of Kewan Pharma e company news, WuXi Biologics news, WuXi Biologics and Kewan Pharma today announced that they have reached a number of strategic cooperation. According to the agreement, WuXi Biologics will absorb the Suzhou process development and pilot production facilities of Kewang Pharmaceuticals, and further build it into a macromolecule development and GMP production service base with industry-leading service standards. At the same time, the two parties signed a strategic partnership service agreement, and WuXi Biologics will provide integrated R&D and production services as an exclusive CDMO partner to ensure the development and production needs of Kewan Pharmaceutical's global innovative drug pipeline. This base will become MFG22, the 22nd biopharmaceutical stock solution production plant in WuXi Biologics' global layout. |